Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 251

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 251
---
 7)      |     | $ |        - |     | $ |        2,054 |
| Accrued expenses              |     |   |      733 |     |   |          518 |
| Accrued employee compensation |     |   |        - |     |   |            3 |
| Other payables                |     |   |        - |     |   |            1 |
| Total                         |     | $ |      733 |     | $ |        2,576 |

| NOTE 4:- | CONVERTIBLE NOTES |

During 2020, the Company entered into
various Convertible Loan Agreements (the “2020 CLAs”). As of December 31, 2023, the Company received $900 from the issuance
of convertible notes (the “2020 Notes”) under the 2020 CLAs.

<div align='center'>F-9</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 4:- | CONVERTIBLE NOTES (Cont.) |

On January 3, 2024, the Company extended
the due date until April 30, 2024 and, subsequently on April 26, 2024 further extended the due date until May 27, 2024. In October 2024,
the Company signed an addendum to the 2020 CLA agreement to extend the maturity date until March 31, 2025 (see also Note 8).

The Company estimates the fair value
of the 2020 Notes using the Probability-Weighted Expected Return Method (“PWERM”). For the six months ended June 30, 2024
and 2023, the Company recorded an income of $4,867 and an expense of $2,046 for the revaluation of such 2020 Notes, within financial
income, net in the statements of comprehensive loss.

A summary of significant unobservable
inputs (Level 3 inputs) used in measuring the fair value of 2020 Notes outstanding are as follows:

|                  |     |   |  June 30, 
      2024 |   |     |   | December 31, 
         2023 |   |
|:-----------------|:----|:--|----------:|:--|:----|:--|